Crinetics Pharmaceuticals (CRNX) Competitors

$84.95 0.00 (0.00%)

As of 09/1/2026

CRNX vs. ZTS, VTRS, JAZZ, NBIX, and ELAN

Should you buy Crinetics Pharmaceuticals stock or one of its competitors? Crinetics Pharmaceuticals's main competitors and comparable companies include Zoetis (ZTS), Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Crinetics Pharmaceuticals compare to Zoetis?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Zoetis (NYSE:ZTS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

In the previous week, Zoetis had 16 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 16 mentions for Zoetis and 0 mentions for Crinetics Pharmaceuticals. Zoetis' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Zoetis is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
Zoetis	Positive

Zoetis has a net margin of 27.49% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Zoetis' return on equity of 74.89% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Zoetis	27.49%	74.89%	18.59%

Crinetics Pharmaceuticals currently has a consensus price target of $81.00, indicating a potential downside of 4.65%. Zoetis has a consensus price target of $101.08, indicating a potential upside of 41.30%. Given Zoetis' stronger consensus rating and higher possible upside, analysts plainly believe Zoetis is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zoetis has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Zoetis	$9.47B	3.12	$2.67B	$6.07	11.78

Crinetics Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Summary

Zoetis beats Crinetics Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Viatris has a net margin of -2.79% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Viatris' return on equity of 20.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Crinetics Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.36	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

In the previous week, Viatris had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Viatris and 0 mentions for Crinetics Pharmaceuticals. Viatris' average media sentiment score of 0.61 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Positive
Crinetics Pharmaceuticals	Neutral

Viatris has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Viatris presently has a consensus target price of $18.71, indicating a potential upside of 10.41%. Crinetics Pharmaceuticals has a consensus target price of $81.00, indicating a potential downside of 4.65%. Given Viatris' stronger consensus rating and higher probable upside, equities analysts plainly believe Viatris is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Summary

Viatris beats Crinetics Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 0 mentions for Crinetics Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.44 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Jazz Pharmaceuticals	Neutral
Crinetics Pharmaceuticals	Neutral

Jazz Pharmaceuticals has a net margin of 20.45% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Jazz Pharmaceuticals' return on equity of 33.97% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Jazz Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Jazz Pharmaceuticals presently has a consensus target price of $286.72, suggesting a potential upside of 19.10%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.65%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Jazz Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Jazz Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.66	-$356.15M	$14.50	16.60
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Summary

Jazz Pharmaceuticals beats Crinetics Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, suggesting a potential downside of 4.65%. Neurocrine Biosciences has a consensus target price of $201.09, suggesting a potential upside of 37.52%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

In the previous week, Neurocrine Biosciences had 15 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 15 mentions for Neurocrine Biosciences and 0 mentions for Crinetics Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.87 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
Neurocrine Biosciences	Positive

Neurocrine Biosciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Neurocrine Biosciences	$2.86B	5.20	$478.60M	$6.82	21.44

Neurocrine Biosciences has a net margin of 20.91% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Neurocrine Biosciences' return on equity of 22.43% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Summary

Neurocrine Biosciences beats Crinetics Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Elanco Animal Health?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Elanco Animal Health has a net margin of -3.96% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Elanco Animal Health's return on equity of 8.13% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Elanco Animal Health	-3.96%	8.13%	3.99%

Crinetics Pharmaceuticals currently has a consensus target price of $81.00, indicating a potential downside of 4.65%. Elanco Animal Health has a consensus target price of $29.09, indicating a potential upside of 29.92%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Elanco Animal Health has higher revenue and earnings than Crinetics Pharmaceuticals. Elanco Animal Health is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Elanco Animal Health	$4.72B	2.37	-$232M	-$0.41	N/A

In the previous week, Elanco Animal Health had 10 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 0 mentions for Crinetics Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.66 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
Elanco Animal Health	Positive

Crinetics Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Summary

Elanco Animal Health beats Crinetics Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRNX vs. The Competition

Export

Metric	Crinetics Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.01B	$12.54B	$7.26B	$13.13B
Dividend Yield	N/A	2.63%	2.56%	12.94%
P/E Ratio	-16.86	792.21	273.80	25.39
Price / Sales	1,170.54	945.09	692.79	108.43
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	7.56	10.49	10.45	6.33
Net Income	-$465.32M	$2.81B	$3.48B	$358.24M
7 Day Performance	N/A	2.81%	0.88%	1.17%
1 Month Performance	0.31%	2.47%	-1.58%	-2.59%
1 Year Performance	150.80%	3.95%	18.09%	5.97%

Crinetics Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRNX Crinetics Pharmaceuticals	1.0087 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210
ZTS Zoetis	4.5637 of 5 stars	$75.70 -0.1%	$107.43 +41.9%	-51.4%	$31.33B	$9.47B	12.47	14,500
VTRS Viatris	2.327 of 5 stars	$16.88 flat	$17.50 +3.7%	+71.9%	$19.39B	$14.30B	N/A	30,000	Analyst Forecast
JAZZ Jazz Pharmaceuticals	4.3388 of 5 stars	$246.81 flat	$285.44 +15.7%	+83.5%	$16.02B	$4.27B	17.02	2,890
NBIX Neurocrine Biosciences	4.7792 of 5 stars	$155.64 flat	$201.05 +29.2%	+0.4%	$15.82B	$2.86B	22.82	2,000	Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRNX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. ZTS, VTRS, JAZZ, NBIX, and ELAN

How does Crinetics Pharmaceuticals compare to Zoetis?

Summary

How does Crinetics Pharmaceuticals compare to Viatris?

Summary

How does Crinetics Pharmaceuticals compare to Jazz Pharmaceuticals?

Summary

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Crinetics Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. ZTS, VTRS, JAZZ, NBIX, and ELAN

How does Crinetics Pharmaceuticals compare to Zoetis?

Does the media prefer CRNX or ZTS?

Is CRNX or ZTS more profitable?

Do analysts recommend CRNX or ZTS?

Do institutionals & insiders believe in CRNX or ZTS?

Which has stronger valuation & earnings, CRNX or ZTS?

Which has more risk and volatility, CRNX or ZTS?

Summary

How does Crinetics Pharmaceuticals compare to Viatris?

Do institutionals and insiders believe in VTRS or CRNX?

Is VTRS or CRNX more profitable?

Which has preferable valuation and earnings, VTRS or CRNX?

Does the media refer more to VTRS or CRNX?

Which has more volatility and risk, VTRS or CRNX?

Do analysts prefer VTRS or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Jazz Pharmaceuticals?

Does the media favor JAZZ or CRNX?

Is JAZZ or CRNX more profitable?

Which has more volatility and risk, JAZZ or CRNX?

Do analysts recommend JAZZ or CRNX?

Do insiders & institutionals have more ownership in JAZZ or CRNX?

Which has higher valuation & earnings, JAZZ or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Do institutionals and insiders have more ownership in CRNX or NBIX?

Do analysts prefer CRNX or NBIX?

Which has more risk & volatility, CRNX or NBIX?

Does the media refer more to CRNX or NBIX?

Which has better earnings & valuation, CRNX or NBIX?

Is CRNX or NBIX more profitable?

Summary

How does Crinetics Pharmaceuticals compare to Elanco Animal Health?

Is CRNX or ELAN more profitable?

Do analysts prefer CRNX or ELAN?

Do insiders and institutionals believe in CRNX or ELAN?

Which has preferable earnings and valuation, CRNX or ELAN?

Does the media refer more to CRNX or ELAN?

Which has more volatility & risk, CRNX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools